Founded in 1998, SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma.

The Scibase method is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Nevisense is a point-of-care device that has emerged from more than 20 years of academic research at Karolinska Institutet Stockholm and significantly increases the physician’s ability to detect and monitor skin tissue alterations. Nevisense has strong protections through a comprehensive patent portfolio and several other combined approaches that relate to technical and clinical development.

Three consecutive and comprehensive clinical studies have been performed to date for Nevisense, with excellent clinical results. A successful pivotal study was finalized in 2012 including 1,951 patients and 2,416 lesions at 22 sites in Europe and US.